Skip to main content

Organon & Co Value Stock - Dividend - Research Selection

Organon & company

ISIN: US68622V1061 , WKN: A3CPKP

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Organon: Deep Value With No Clear Catalysts

2025-12-19
Organon shares trade at a discount, but there are no strong drivers for business growth. Click here to find out why I am neutral on OGN stock.

Healthcare Dashboard For December And Focus On PJP

2025-12-14
Discover 10 undervalued healthcare stocks and why pharmaceuticals and providers stand out for value and quality.

Barclays Initiates Coverage of Organon (OGN) with Underweight Recommendation

2025-12-10

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

2025-12-03
Organon & Co. (OGN) Piper Sandler 37th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsJoseph Morrissey - Interim CEO...

Tax-Loss Pouncing

2025-11-24
Harvesting tax losses is a way to close out losing positions before the new year. Read more here...

IHF: Healthcare Dashboard For November

2025-11-19
Healthcare providers are undervalued. Click here to find out which stocks are the cheapest and if the IHF ETF is a risky buy.

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend

2025-11-17
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Organon & Co...

Henlius and Organon score first US Perjeta biosimilar approval

2025-11-17
The FDA’s verdict on Poherdy comes amid Perjeta creator Genentech’s patent infringement lawsuit against Organon and Shanghai Henlius Biotech.

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

2025-11-17
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.[1] POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality

Value Investing And Benjamin Graham

2025-11-17
Value investing has been the method by which long-term investors have made money in all kinds of markets. However, value investing has rarely been as unpopular as it is today. Read more here